SRNE Sorrento Therapeutics
- 0.011
- -0.002-15.38%
Sorrento Therapeutics News
Biotech Bankruptcies Hit a Record Despite Sector's Recovery
Reported Earlier, Scilex Announces Move To Extend Lockup Period For Sorrento-Distributed Dividend Shares Until September 2024
- Scilex Holding Company (NASDAQ:SCLX, " Scilex" ))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatm
Sorrento Faked Venue in Bankruptcy Filing, Justice Department Says
Overview of Sorrento Therapeutics' RTX (MCP-101, Resiniferatoxin) Drug Across the 7MM, 2023-2032
Scilex Seeks Health Canada Approval for Migraine Therapy
Virpax Pharmaceuticals Gets Non-compliance Notice From Nasdaq
Sorrento Therapeutics Board Member Resigns Citing Lack of Communication on Restructuring
By Ben Glickman Sorrento Therapeutics said director Tammy Reilly resigned Oct. 25 citing a lack of communication from the bankrupt company's chief restructuring officer. The pharmaceutical company s
Scilex Files Emergency Motion in Sorrento Bankruptcy Case
By Josh Beckerman Scilex Holding, a subsidiary of bankrupt drugmaker Sorrento Therapeutics, said it filed an emergency motion in bankruptcy court related to its allegations that possible naked short
Celularity CEO Acquires Stock Worth ~$3M
Scilex Holding Company Provides Notice To All Record Holders And Beneficial Owners Of Restricted Shares Of Scilex Holding Company
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants That Sorrento Held in Scilex Holding Company
Scilex Assumed $100M In Debt Owed To Oramed Pharmaceuticals And Issued A Promissory Note And Warrants To Oramed As Part Of The Securities Transfer.
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
Press Release: Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of All of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento").
Scilex Holding's Phase 2 Trial Shows Safety, Efficacy of Treatment for Lower Back Pain
Scilex Holding (SCLX) said Thursday the completed phase 2 trial of SP-103 showed the safety and efficacy of the treatment for moderate to severe acute lower back pain. Preliminary analysis showed that
Scilex to Acquire Sorrento-owned Stake
Scilex Holding Company Enters Non-Binding Term Sheets For The Purchase Of All Of The Scilex Common Shares, Preferred Shares, And Warrants Currently Owned By Sorrento Therapeutics, Inc. And Is Declared New Successful Bidder
Scilex Holding Company Enters Non-Binding Term Sheets For The Purchase Of All Of The Scilex Common Shares, Preferred Shares, And Warrants Currently Owned By Sorrento Therapeutics, Inc. And Is Declared
Sorrento COVID Pill Meets Late-stage Trial Goal
Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV
Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution). The conference was held from September 6-8, 2023 in Las Vegas, NV.
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.
Sorrento Granted Court Approval to Sell Scilex Stock
Analysis
Price Target
No Data
